(Bloomberg) -- Life-sciences company Danaher Corp. has stopped pursuing Catalent Inc. after expressing interest in buying the contract manufacturer, according to people familiar with the matter.
Despite a multi-billion-dollar takeover bid from Novo Holdings, contract manufacturer Catalent appears to be continuing with the internal restructuring scheme it unveiled last year. For more than ...
(Bloomberg) -- Life sciences company Danaher Corp. has expressed takeover interest in contract manufacturer Catalent Inc., according to people familiar with the matter. Most Read from Bloomberg ...
Danaher Corp (NYSE: DHR) has logged Q1 FY23 adjusted EPS of $2.36, down from $2.76 a year ago, surpassing the consensus of $2.25. Sales decreased 7% Y/Y to $7.17 billion, beating the consensus of ...
That means you can get tickets to see the Magic at half price! Act fast, as this offer is available for a limited time only. Wednesday, Mar. 13 7:00 PM Tuesday, Mar. 19 7:00 PM Thursday, Mar. 21 7 ...
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical ...
Thousands of Houston ISD students have left the district since the Texas Education Agency's takeover, on top of an already declining enrollment, amounting to a 12 percent drop in students over the ...
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer ...
The Taliban has taken control of Kabul, the capital of Afghanistan. Here’s what a Taliban regime means for the US and rest of the world. With the Taliban in power, Afghan women, journalists and ...
Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments ...
No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...